252 related articles for article (PubMed ID: 29588471)
1. Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis.
Pei H; He L; Shao M; Yang Z; Ran Y; Li D; Zhou Y; Tang M; Wang T; Gong Y; Chen X; Yang S; Xiang M; Chen L
Sci Rep; 2018 Mar; 8(1):5273. PubMed ID: 29588471
[TBL] [Abstract][Full Text] [Related]
2. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
He L; Pei H; Lan T; Tang M; Zhang C; Chen L
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
[TBL] [Abstract][Full Text] [Related]
3. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY
Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis.
Shan S; Zhou Y; Yu J; Yang Q; Pan D; Wang Y; Li L; Zhu J; Zhang Y; Huang S; Li Z; Ning Z; Xin L; Lu X
Int Immunopharmacol; 2019 Dec; 77():105914. PubMed ID: 31634789
[TBL] [Abstract][Full Text] [Related]
7. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
8. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
9. Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors.
Dai J; Yang L; Addison G
Mini Rev Med Chem; 2019; 19(18):1531-1543. PubMed ID: 31288716
[TBL] [Abstract][Full Text] [Related]
10. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
Mohamed MF; Beck D; Camp HS; Othman AA
J Clin Pharmacol; 2020 Feb; 60(2):188-197. PubMed ID: 31448433
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.
Liang T; Cen L; Wang J; Cheng M; Guo W; Wang W; Yu C; Zhang H; Wang Y; Hao Z; Jin J; Wu Y; Jiang T; Zhu Q; Xu Y
Bioorg Med Chem; 2023 Dec; 96():117354. PubMed ID: 37944414
[TBL] [Abstract][Full Text] [Related]
12. Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.
McDonnell ME; Bian H; Wrobel J; Smith GR; Liang S; Ma H; Reitz AB
Bioorg Med Chem Lett; 2014 Feb; 24(4):1116-21. PubMed ID: 24461299
[TBL] [Abstract][Full Text] [Related]
13. Identification of HHT-9041P1: A novel potent and selective JAK1 inhibitor in a rat model of rheumatoid arthritis.
Zhang X; Xu X; Chen J; Wang G; Li Q; Li M; Lu J
Int Immunopharmacol; 2023 Dec; 125(Pt A):111086. PubMed ID: 37883818
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibitors of the Janus kinase Jak3--Are they effective?
Thoma G; Drückes P; Zerwes HG
Bioorg Med Chem Lett; 2014 Oct; 24(19):4617-4621. PubMed ID: 25217444
[TBL] [Abstract][Full Text] [Related]
16. Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors.
Bahekar R; Panchal N; Soman S; Desai J; Patel D; Argade A; Gite A; Gite S; Patel B; Kumar J; S S; Patel H; Sundar R; Chatterjee A; Mahapatra J; Patel H; Ghoshdastidar K; Bandyopadhyay D; Desai RC
Bioorg Chem; 2020 Jun; 99():103851. PubMed ID: 32334196
[TBL] [Abstract][Full Text] [Related]
17. Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.
Hynes J; Wu H; Kempson J; Duan JJ; Lu Z; Jiang B; Stachura S; Tokarski JS; Sack JS; Khan JA; Lippy JS; Zhang RF; Pitt S; Shen G; Gillooly K; McIntyre K; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; Fura A; Schieven GL; Pitts WJ; Wrobleski ST
Bioorg Med Chem Lett; 2017 Jul; 27(14):3101-3106. PubMed ID: 28539220
[TBL] [Abstract][Full Text] [Related]
18. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Qiu Q; Feng Q; Tan X; Guo M
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):547-554. PubMed ID: 31059310
[No Abstract] [Full Text] [Related]
19. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
[TBL] [Abstract][Full Text] [Related]
20. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
